Table 1 Adherence of health practice guidelines (HPGs) to RIGHT checklist items addressing the domains of basic information and background (total number and percentage with 95% confidence intervals (CI) of addressed items)
RIGHT checklist item | Croatian HPGs (n = 26) | European HPGs (n = 24) | Pa | BF10b |
|---|---|---|---|---|
Domain 1: Basic information | ||||
Title/subtitle | Total number (%, 95% CI) | |||
1a—Identify the report as a guideline, that is, with “guideline(s)” or “recommendation(s)” in the title. | 26 (100.0, 87.3–100.0) | 22 (91.7, 74.2–97.6) | 0.130 | 0.34 |
1b—Describe the year of publication of the guideline. | 1 (3.8, 2.0–21.6) | 3 (12.5, 4.0–31.0) | 0.260 | 0.33 |
1c—Describe the focus of the guideline, such as screening, diagnosis, treatment, management, prevention or others. | 26 (100.0, 87.3–100.0) | 21 (87.5, 69.0–95.7) | 0.063 | 0.73 |
Executive summary | ||||
2—Provide a summary of the recommendations contained in the guideline. | 10 (38.4, 20.9–59.3) | 17 (70.8, 50.8–85.1) | 0.022 | 4.44 |
Abbreviations and acronyms | ||||
3—Define new or key terms, and provide a list of abbreviations and acronyms if applicable. | 4 (15.3, 5.0–35.7) | 4 (16.7, 6.7–35.9) | 0.902 | 0.26 |
Corresponding developer | ||||
4—Identify at least one corresponding developer or author who can be contacted about the guideline. | 26 (100.0, 87.3–100.0) | 23 (95.8, 79.8–99.3) | 0.293 | 0.16 |
Domain 2: Background | ||||
Brief description of the health problem(s) | ||||
5—Describe the basic epidemiology of the problem, such as the prevalence/incidence, morbidity, mortality, and burden (including financial) resulting from the problem. | 23 (88.4, 68.7–96.9) | 22 (91.7, 74.2–97.6) | 0.706 | 0.22 |
Aim(s) of the guideline and specific objectives | ||||
6—Describe the aim(s) of the guideline and specific objectives, such as improvements in health indicators (e.g., mortality and disease prevalence), quality of life, or cost savings. | 20 (76.9, 55.9–90.2) | 9 (37.5, 21.2–57.3) | 0.005 | 16.90 |
Target population(s) | ||||
7a—Describe the primary population(s) that is addressed by the recommendation(s) in the guideline. | 22 (84.6, 64.3–94.9) | 22 (91.7, 74.2–97.6) | 0.443 | 0.29 |
7b—Describe any subgroups that are given special consideration in the guideline. | 20 (76.9, 55.9–90.2) | 15 (62.5, 42.7–78.8) | 0.266 | 0.57 |
End-users and settings | ||||
8a—Describe the intended primary users of the guideline (such as primary care providers, clinical specialists, public health practitioners, program managers, and policy-makers) and other potential users of the guideline. | 12 (46.2, 27.1–66.3) | 3 (12.5, 4.0–31.0) | 0.009 | 8.70 |
8b—Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or in-patient facilities. | 8 (30.7, 15.1–51.9) | 4 (16.7, 6.7–35.9) | 0.243 | 0.55 |
Guideline development groups | ||||
9a—Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewer, systematic review team, and methodologists). | 4 (15.3, 0.5 to 35.7) | 3 (12.5, 4.0–31.0) | 0.769 | 0.25 |
9b—List all individuals involved in developing the guideline, including their title, role(s) and institutional affiliation(s). | 26 (100.0, 87.3–100.0) | 23 (95.8, 79.8–99.3) | 0.293 | 0.16 |